AkzoNobel Q2 Results 2014 AMSTERDAM, Netherlands, July 23,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AkzoNobel Q2 Results 2014

AMSTERDAM, Netherlands, July 23, 2014 (GLOBE NEWSWIRE) -- July 23, 2014  

  • Volumes positive in all three Business Areas
  • Revenue down 4 percent, mainly due to 5 percent adverse currency effects
  • Operating income €353 million (2013: €322 million) reflecting increased volume and benefits from improvement actions
  • Return on sales (ROS) improved from 8.3 percent to 9.5 percent. Restructuring costs were €45 million (2013: €40 million). Excluding these, ROS is 10.7 percent (2013: 9.3 percent)
  • Net income attributable to shareholders was €205 million (2013: €184 million on a comparable basis), mainly due to higher operating income
  • Adjusted EPS increased 23 percent to €0.95 (2013: €0.77 adjusted for an incidental tax gain)
  • Net cash inflow from operating activities was €393 million (2013: €261 million)
  • On track to deliver 2015 targets despite a strong euro and the expected continued fragile economic environment in 2014

Q2 2014 in € million

  Q2 2013 Q2 2014 D%
Revenue 3,865 3,710 (4)
Operating income 322 353 10
Return on sales (ROS) % 8.3 9.5  
EBITDA 474 509 7
Net income attributable to shareholders*
 
184 205 11

H1 2014 in € million

  H1 2013 H1 2014 D%
Revenue 7,330 7,093 (3)
Operating income 539 569 6
Return on sales (ROS) % 7.4 8.0  
EBITDA 849 873 3
Net income attributable to shareholders* 280 334 19

* Excluding discontinued operations and a deferred tax gain

Akzo Nobel N.V. (AkzoNobel) today reported positive volume development in all three Business Areas. Second quarter revenue of €3,710 million was 4 percent lower compared with the same quarter last year. The decrease was mainly due to 5 percent adverse currency effects.

Operating income improved 10 percent to €353 million (2013: €322 million), leading to an increase in net income attributable to shareholders of €205 million (2013: €184 million on a comparable basis). Excluding restructuring costs, return on sales improved in all three Business Areas, with an overall ROS of 9.5 percent (2013: 8.3 percent).

CEO Ton Büchner said:

"With the publication of the Q2 figures, the results of our ongoing commitment to organic growth and operational efficiency continue to be visible. We are operating in a volatile market, but we managed to increase volumes in all three Business Areas, and for the fourth consecutive quarter we saw positive progress in our year-on-year ROS. Compared to 2013, net income attributable to shareholders increased on a comparable basis. This quarter also highlighted some great examples of AkzoNobel's commitment to innovation and sustainability, such as the opening of our new membrane electrolysis plant in Germany, the €6.5 million investment to expand the research center at our Performance Coatings site in China, and the start-up of our new €80 million Imperatriz Chemical Island in Brazil. We also launched our Human Cities initiative. These developments will not only help to further enhance our operational efficiency and stimulate organic growth, but will also boost our market leading positions, ensuring that we are on track to deliver on  our 2015 financial targets."

In Decorative Paints , volumes rose by 3 percent, mainly because of increased volumes in Asia and most European countries. Revenue declined 9 percent compared with 2013, due to the divestment of Building Adhesives and a 5 percent adverse currency effect. Operating income was at the same level as last year, although when the effect of divestments and adverse currency developments are excluded, it increased on a comparable basis.  The ongoing operational excellence measures in Europe continue to support the improvements in margin.

Volumes in Performance Coatings rose 1 percent compared with 2013. Revenue declined 2 percent, with the improvements in volume and price/mix being offset by adverse currencies. Operating income improved 9 percent, due to operating effectiveness measures, which offset increased restructuring costs and an adverse currency impact. Return on sales was 12.4 percent (2013: 11 percent).

Volumes in Specialty Chemicals increased 4 percent due to better market conditions in most businesses, with Pulp and Performance Chemicals and Functional Chemicals showing strong growth. Revenue declined, mainly due to adverse currency developments and continued caustic price pressure. Operating income increased 2 percent compared with 2013 due to cost control and operational efficiencies.

Business area highlights

  Decorative Paints
Q2 2013 Q2 2014 D%   H1 2013 H1 2014 D%
1,179 1,074 (9) Revenue 2,104 1,939 (8)
102 102 - Operating Income 145 119 (18)
8.7 9.5   ROS % 6.9 6.1  
141 141 - EBITDA 229 197 (14)
             
  Performance Coatings
Q2 2013 Q2 2014 D%   H1 2013 H1 2014 D%
1,458 1,434 (2) Revenue 2,789 2,753 (1)
163 178 9 Operating Income 292 304 4
11.2 12.4   ROS % 10.5 11.0  
197 212 8 EBITDA 360 375 4
             
  Specialty Chemicals
Q2 2013 Q2 2014 D%   H1 2013 H1 2014 D%
1,253 1,228 (2) Revenue 2,497 2,450 (2)
121 124 2 Operating Income 220 259 18
9.7 10.1   ROS % 8.8 10.6  
198 204 3 EBITDA 372 408 10
             

Outlook

We are on track to deliver on our 2015 targets despite a strong euro and the expected continued fragile economic environment in 2014.

The Q2 2014 report can be downloaded via the AkzoNobel Report iPad app http://bit.ly/obljrf or read online at www.akzonobel.com/quarterlyresults .

- - -

AkzoNobel is a leading global paints and coatings company and a major producer of specialty chemicals. We supply industries and consumers worldwide with innovative products and are passionate about developing sustainable answers for our customers. Our portfolio includes well-known brands such as Dulux, Sikkens, International and Eka. Headquartered in Amsterdam, the Netherlands, we are consistently ranked as one of the leaders in the area of sustainability. With operations in more than 80 countries, our 50,000 people around the world are committed to delivering leading products and technologies to meet the growing demands of our fast-changing world.

Not for publication - for more information

Corporate Media Relations Corporate Investor Relations
T +31 (0)20 - 502 7833 T +31 (0)20 - 502 7854
Contact: Diana Abrahams Contact: Sheryl Stokes

Safe Harbor Statement

This press release contains statements which address key issues such as AkzoNobel's growth strategy, future financial results, market positions, product development, products in the pipeline and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our latest annual report, a copy of which can be found on our website www.akzonobel.com

AkzoNobel Q2 2014 Report http://hugin.info/130660/R/1833792/636941.pdf
AkzoNobel Press Release Q2 2014 http://hugin.info/130660/R/1833792/636942.pdf

HUG#1833792

Scroll down for more posts ▼

Top 10 Most Recent News Articles

EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 718

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 97

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 302

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 158

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 410

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 262

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 216

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 385

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading

Top 5 Most Recently Viewed Articles

Blend's AWS Financial Services Competency Enhances Innovations

Updated Category News Views 152

Blend Takes a Major Stride with AWS Financial Services Competency Exciting news emerges from Blend as the company secures a crucial recognition in the cloud technology arena. They've recently achieved the prestigious AWS Financial Services Competency badge, a testament to their outstanding expertise and remarkable track record in delivering innovative, secure, and...

Continue Reading
The Upcoming Surge of Last Mile Delivery Market Growth

Updated Category News Views 289

Overview of the Last Mile Delivery Market Growth The Last Mile Delivery market is poised for significant growth in the coming years, projected to rise by USD 51.1 billion from 2025 to 2029. This increase is primarily driven by the expanding global e-commerce sector and the integration of advanced technologies, including AI, which are transforming logistical operations....

Continue Reading
Tide Rock Expands Its Precision Machining Horizons Through Acquisitions

Updated Category News Views 326

Tide Rock Expands Its Precision Machining Horizons Tide Rock has taken a significant leap forward in the field of advanced precision machining through its recent acquisitions. By acquiring Precision Waterjet & Laser, now known as Precision Advanced Machining, located in Anaheim, California, and Made in America Manufacturing based in Buda, Texas, Tide Rock is enhancing its...

Continue Reading
Novavax Revises Projections, Anticipates Robust Nuvaxovid Demand

Updated Category News Views 149

Novavax Reports Strong Second Quarter Results Recently, Novavax Inc. reported impressive sales of $239.24 million for the second quarter of 2025, marking a significant shift from $415 million during the same period in the previous year. This figure exceeded the Wall Street consensus expectations, which estimated sales at $156.29 million. Such growth highlights Novavax's...

Continue Reading
Insights into Novartis' Cosentyx and GCAptAIN Study Findings

Updated Category News Views 219

Novartis' Groundbreaking Updates on Cosentyx in GCAptAIN Study Novartis has recently provided significant updates regarding the Phase III GCAptAIN study, focusing on the efficacy of Cosentyx (secukinumab) for patients suffering from giant cell arteritis (GCA). This condition, predominantly affecting older adults, poses a risk of severe complications if not managed...

Continue Reading